Introduction
============

Gliomas are primary tumors that originate in the brain or spinal cord, and account for \~80% of all malignant brain tumors ([@b1-ol-0-0-6850],[@b2-ol-0-0-6850]). Gliomas occur mostly in childhood, with symptoms including visual loss, pain, nausea, vomiting, weakness in the extremities, headaches and seizures ([@b3-ol-0-0-6850],[@b4-ol-0-0-6850]). Glioma patients have a low survival rate, and of 10,000 Americans diagnosed with malignant gliomas each year, \~50% survive one year following diagnosis, and 25% two years later ([@b5-ol-0-0-6850]). Therefore, it is essential to explore the molecular mechanisms of glioma and develop effective methods for its treatment.

The methods used to treat gliomas at present are typically a combination of surgery, radiotherapy and chemotherapy, however, the median survival duration of patients with gliomas is only 9--12 months ([@b6-ol-0-0-6850]). Understanding the molecular mechanisms which underlie this disease is crucial for the development of more effective methods for its treatment ([@b7-ol-0-0-6850]). Previous studies revealed that methylation of CpG islands within or near promoters were associated with increased gene expression, and may contribute to tumor formation and progression ([@b8-ol-0-0-6850]--[@b10-ol-0-0-6850]). Costello *et al* ([@b11-ol-0-0-6850]) demonstrated that methylation of the *pl6/CDKN2* tumor suppressor gene was detected in gliomas. Other studies reported that methylation of the promoter in the DNA repair gene O-6-methylguanine-DNA methyltransferase, contributed to the progression of gliomas ([@b12-ol-0-0-6850],[@b13-ol-0-0-6850]). Chen *et al* ([@b14-ol-0-0-6850]) demonstrated that the methylation of the excision repair cross-complementation group 1 promoter promoted the development of gliomas. Although previous studies have made advances in the field, the exact mechanisms of methylation-driven gliomas have not been fully elucidated.

The present study aimed to identify methylation-associated genes from differentially expressed genes between patients with glioma and normal controls, in relation to associated pathways of gliomas, to elucidate the underlying molecular mechanisms. Methylation associated genes were identified from differentially expressed genes (DEGs) by methylation analysis. Significant genes and pathways were selected from the transcriptional regulatory network and sub-pathway enrichment analysis. Through the identification of key genes and pathways, the potential underlying molecular mechanisms and the potential biomarkers of gliomas were explored.

Materials and methods
=====================

### Affymetrix microarray data

The gene expression profile data GSE50021 was downloaded from the Gene Expression Omnibus database (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) ([@b15-ol-0-0-6850]). Gene expression profiling was based on the GPL13938 platform using the Illumina HumanHT-12 WG-DASL V4.0 expression BeadChip (Illumina Inc., San Diego, CA, USA). The array consists of 29,377 probe-sets, which it is possible to use to detect the transcription level of 20,817 human genes. A total of 45 samples, including 10 specimens of normal brain tissues and 35 specimens of glioma tissues from children with a mean age of 1.008±1.910 years were available for the expression array.

The dual channel methylation microarray data GSE50022, was downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b15-ol-0-0-6850]). Gene expression profiling was based on the platform of GPL16304 using the Illumina HumanMethylation450 BeadChip (UBC enhanced annotation v1.0; Illumina, Inc.). The array consisted of 485,512 probe-sets, which detect \>485,000 methylation sites per sample at single-nucleotide resolution. Methylation data of 28 samples from patients with glioma (mean age, 0.943±0.782 years) were analyzed in the present study. The methylation index matrix was processed with GenomeStudio v2011 software (Illumina, Inc.) which indicated the methylation ratios of the probes.

### Identification of differentially expressed genes

The raw expression profile data were initially preprocessed using the impute package in R ([@b16-ol-0-0-6850]). The processed data were normalized using the preprocess Core in R ([@b17-ol-0-0-6850]). DEGs, between normal brain tissues and glioma tissues were analyzed by limma package in R ([@b18-ol-0-0-6850]). The fold change (FC) of the expression of individual genes was also calculated for differential expression test. All genes with a P-value \<0.05 and log^2^ FC \>1 were considered significant and selected as DEGs.

### Screening of key methylation sites

The raw methylation index matrix were initially preprocessed using the impute package in R ([@b16-ol-0-0-6850]). The methylation sites located around the DEGs were screened according to the methylation chip annotation information. Methylation sites which had a methylation index \>0.8 in \>80% of samples were selected. Key methylation sites which were located 50 kb upstream and/or downstream of the transcription start site were screened.

### Transcriptional regulatory network construction

The selected key methylation sites were mapped to the transcription factor binding site data predicted by the University of California Santa Cruz (UCSC) genome browser ([@b19-ol-0-0-6850]), and the methylation information in the transcription factor binding site was obtained. The transcriptional regulatory network was constructed using Cytoscape software (version 3.2.0; Institute for Systems Biology, Seattle, WA, USA) ([@b20-ol-0-0-6850]).

### Survival analysis of key methylation sites

Survival analysis of methylation sites was performed based on the methylation index. The samples were divided into two parts according to the mean of the methylation index: One part had high methylation index (\>0.87); another part had lower methylation index (≤0.87). A Kaplan-Meier curve based on the survival time of the two parts was constructed, and the log-rank test was used to test for a significant difference between the groups with P\<0.05 considered to indicate a statistically significant difference.

### Analysis of risk sub-pathway

Gene Ontology (GO) analysis is a commonly used method for functional studies of large-scale genomic or transcriptomic data ([@b21-ol-0-0-6850]). Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b22-ol-0-0-6850]) is a primary information-based database which stores information concerning how molecules and genes are networked. The Database for Annotation Visualization and Integrated Discovery (DAVID) ([@b23-ol-0-0-6850]) was used to systematically extract biological meaning from large gene or protein lists. GO function and KEGG pathways of downregulated DEGs, regulated by transcription factors were analyzed using DAVID 6.7, with a false discovery rate \<0.05.

With in metabolic pathways, the closer the proximity of components in the network, the greater the potential for similarity of the biological functions. Therefore, identification of the sub-pathway of diseases is critical. The K-clique was used to divide the metabolic pathway into sub-pathways through the iSubpathwayMiner package in R ([@b24-ol-0-0-6850]). Sub-pathways with P\<0.05 were considered significant.

Results
=======

### Identification of differentially expressed genes

Following analysis of the expression profile data, the expression information of 20,727 genes in 45 samples was obtained. The normalized results revealed that the expression median following normalization was a straight line ([Fig. 1](#f1-ol-0-0-6850){ref-type="fig"}). From all the genes recorded, 79 significantly downregulated DEGs were selected. However, no upregulated DEGs were identified.

### Screening of key methylation sites

Following preprocessing of the methylation index matrix, 382,049 methylation sites in 28 samples were detected. A total of 79 significantly downregulated DEGs overlapped with the methylation data, and 1,474 methylation sites associated with DEGs were identified. The methylation signals of 1,187 methylation sites were detected in the methylation chip. A total of 204 methylation sites, which had a methylation index \>0.8 in \>80% of samples were selected. A total of 179 key methylation sites in 65 genes, which were located 50 kb upstream or downstream of the transcription start site, were selected.

### Analysis of the transcriptional regulatory network

According to the UCSC genome browser ([@b19-ol-0-0-6850]), 26 methylation sites were revealed to be located in 42 transcription factor binding sites ([Table I](#tI-ol-0-0-6850){ref-type="table"}). A total of 20 target genes and 36 transcription factors were included in the transcriptional regulatory network ([Fig. 2](#f2-ol-0-0-6850){ref-type="fig"}). Based on this, the glutamate metabotropic receptor 2 (*GRM2*) gene was regulated by 8 transcription factors; the rhomboid-like 3 (*RHBDL3*) gene was regulated by 4 transcription factors and rhomboid 5 homolog 2 (*RHBDF2*) had 2 methylation sites in the transcription factor binding sites.

### Survival analysis of key methylation sites

Survival analysis of the 204 methylation sites demonstrated that cg00157228 significantly affected the survival time of patients. The survival time of patients with lower methylation levels in cg00157228 was increased compared with patients with higher methylation levels in cg00157228 ([Fig. 3](#f3-ol-0-0-6850){ref-type="fig"}). Inositol-triphosphate 3 kinase A (*ITPKA*) was the gene located closest to cg00157228.

### Analysis of risk sub-pathways

GO analysis of 20 target genes confirmed that specific DEGs were significantly enriched in different GO categories, which were associated with biological processes including potassium ion transport, monovalent inorganic cation transport and ion transport ([Table II](#tII-ol-0-0-6850){ref-type="table"}). However, the 20 target genes were not significantly enriched in any pathways. A total of 8 glioma related sub-pathways were mined from the inositol phosphate metabolism pathway. *ITPKA* was the DEG enriched in these 8 sub-pathways ([Fig. 4](#f4-ol-0-0-6850){ref-type="fig"}).

Discussion
==========

Gliomas are the most common malignant tumors of the brain, but the molecular mechanisms underlying the progression of gliomas remain unclear ([@b25-ol-0-0-6850]). In the present study, a bioinformatics approach was used to predict potential therapeutic targets and explore the possible molecular mechanisms involved. A total of 79 DEGs associated with caspase inhibition were identified. By constructing a transcriptional regulatory network and performing analysis of risk sub-pathways and survival analysis of key methylation sites, we identified key genes and pathways were identified, including *GRM2*, *ITPKA* and inositol phosphate metabolism.

*GRM2* is a protein-coupled receptor, and is associated with diseases that include schizophrenia ([@b26-ol-0-0-6850]). *GRM2* is expressed in the foetal and the adult brain, and is associated with inhibition of the cyclic adenosine monophosphate pathway ([@b27-ol-0-0-6850]). Meldrum *et al* ([@b28-ol-0-0-6850]) demonstrated that L-glutamate activates metabotropic glutamate receptors and functions as the main excitatory neurotransmitter in the central nervous system. Ullian *et al* ([@b29-ol-0-0-6850]) revealed that glutamate receptors may be involved in synaptogenesis or synaptic stabilization. Glutamatergic neurotransmission has been reported to participate in the majority of normal brain functions ([@b30-ol-0-0-6850]). Furthermore, previous studies have demonstrated that glioma is a primary central nervous system associated cancer ([@b31-ol-0-0-6850],[@b32-ol-0-0-6850]). According to a previous study, the downregulation of *GRM2* may be caused by methylation in the promoter, and *GRM2* downregulation may promote the progression of gliomas ([@b33-ol-0-0-6850]). In the present study, *GRM2* was downregulated in glioma cells, and 8 methylation sites were identified in the promoter region of *GRM2*. Transcriptional regulatory networks revealed that methylation in the promoter of *GRM2* may influence the binding of 8 transcription factors. Furthermore, *GRM2* may be a potential therapeutic target in the treatment of gliomas. Arcella *et al* ([@b34-ol-0-0-6850]) revealed that pharmacological blockade of group II metabotropic glutamate receptors reduced the growth of glioma cells *in vivo*.

Inositol phosphate metabolism was the selected sub-pathway in the present study. Tilly *et al* ([@b35-ol-0-0-6850]) demonstrated that stimulation of human epidermoid carcinoma cells using bradykinin, results in very rapid release of inositol phosphates. Lee *et al* ([@b36-ol-0-0-6850]) revealed that changes in inositol phosphate metabolism are associated with neoplasia in mouse keratinocytes. Mishra *et al* ([@b37-ol-0-0-6850]) demonstrated that inositol phosphates trigger numerous cellular processes by regulating calcium release from internal stores. Another previous study revealed that calcium imbalance is associated with gastric cancer ([@b38-ol-0-0-6850]). The results of the present study provide evidence that inositol phosphate metabolism was the enriched pathway associated with methylation-induced gene silencing. Thus, inositol phosphate metabolism may be a potential candidate pathway for the treatment of gliomas.

*ITPKA* is responsible for regulating a large number of inositol polyphosphates that are important in cellular signaling ([@b39-ol-0-0-6850]). Kato *et al* ([@b39-ol-0-0-6850]) indicated that *ITPKA* was downregulated in oral squamous cell carcinoma, and may be a potential novel molecular target. Windhorst *et al* ([@b40-ol-0-0-6850]) demonstrated that *ITPKA* was a novel cell motility-promoting protein that increased the metastatic potential of tumor cells. In the present study, *ITPKA* was downregulated and was enriched in the inositol phosphate metabolism pathway. Survival analysis revealed the survival time of patients with lower methylation levels in cg00157228 was longer than patients with higher methylation levels in cg00157228. *ITPKA* was the nearest gene to cg00157228. Taken together, these results indicated that downregulation of *ITPKA* due to methylation in cg00157228 may be a potential molecular mechanism involved in the development of gliomas, and may be a potential therapeutic target for novel treatments.

In conclusion, *GRM2*, *ITPKA* and inositol phosphate metabolism may contribute to the progression of gliomas. Furthermore, the present study provides an additional mechanism underlying methylation-induced gliomas, which is that methylation results in the dysregulation of specific transcripts. However, further experiments are required to confirm these results.

![Boxplot of normalized expression values for the dataset. The dotted line in the middle of each box represents the median of each sample, and its distribution among samples indicates the level of normalization of the data, with a straight line revealing a fair normalization level. (A) Data before normalization. (B) Data after normalization.](ol-14-05-5203-g00){#f1-ol-0-0-6850}

![Transcriptional regulatory network analysis. Yellow triangle nodes represent transcription factors, purple circle nodes represent target genes, arrows represent the transcriptional regulation relationship, and repeated connection lines represent 2 methylation sites in the transcription factor binding sites.](ol-14-05-5203-g01){#f2-ol-0-0-6850}

![Prediction of survival probabilities based on cg00157228 methylation, as assessed using KM analysis. The significance was determined using the log-rank test. KM, Kaplan-Meier.](ol-14-05-5203-g02){#f3-ol-0-0-6850}

###### 

Sub-pathway enrichment analysis of differentially expressed genes. Digital nodes refer to enzymes; letter nodes refer to genes; node with red borders refer to DEGs enriched in the pathway; lines represent the interactions of genes in the networks. Sub-pathway enrichment analysis of differentially expressed genes. Digital nodes refer to enzymes; letter nodes refer to genes; node with red borders refer to DEGs enriched in the pathway; lines represent the interactions of genes in the networks.
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###### 

Key methylation site information.

  ID           Chromosome   MAPINFO     tfbs_start   tfbs_end    tf              Distance_closest_TSS   Closest_TSS_gene_name
  ------------ ------------ ----------- ------------ ----------- --------------- ---------------------- -----------------------
  cg06191091   chr17        30583855    30583848     30583862    *USF*           −9339                  *RHBDL3*
  cg02629157   chr9         138670609   138670546    138670568   *TCF11*         25013                  *KCNT1*
  cg11709150   chr1         2440438     2440431      2440444     *TCF11*         10256                  *PLCH2*
  cg04585209   chr11        6292311     6292257      6292272     *TAXCREB*       306                    *CCKBR*
  cg07125541   chr12        113534668   113534663    113534687   *STAT5A*        38736                  *RASAL1*
  cg10707626   chr3         51747098    51747027     51747051    *STAT5A*        6018                   *GRM2*
  cg06191091   chr17        30583855    30583849     30583860    *SREBP1*        −9339                  *RHBDL3*
  cg12603173   chr11        64508421    64508409     64508423    *RREB1*         −66                    *RASGRP2*
  cg11025960   chr3         51749188    51749177     51749195    *RFX1*          8108                   *GRM2*
  cg10692302   chr3         51747227    51747224     51747245    *PPARG*         6147                   *GRM2*
  cg02629157   chr9         138670609   138670558    138670569   *POU6F1*        25013                  *KCNT1*
  cg11014582   chr6         76333727    76333675     76333696    *PAX6*          −852                   *LMO7*
  cg04341461   chr1         2410006     2409978      2410006     *PAX5*          −1616                  *PLCH2*
  cg05289873   chr17        40321636    40321576     40321597    *PAX4*          11660                  *KCNH4*
  cg10692302   chr3         51747227    51747222     51747252    *PAX4*          6147                   *GRM2*
  cg04625615   chr15        41788368    41788310     41788330    *P53*           2313                   *ITPKA*
  cg07200386   chr8         22079169    22079113     22079135    *OLF1*          10682                  *PHYHIP*
  cg11014582   chr6         76333727    76333676     76333683    *NKX25*         −852                   *LMO7*
  cg09864712   chr16        726786      726720       726749      *MYOGNF1*       712                    *RHBDL1*
  cg06191091   chr17        30583855    30583848     30583862    *MYCMAX*        −9339                  *RHBDL3*
  cg00810908   chr3         13612319    13612306     13612320    *MEIS1AHOXA9*   2080                   *FBLN2*
  cg11025960   chr3         51749188    51749181     51749190    *LMO2COM*       8108                   *GRM2*
  cg03358506   chr8         22058702    22058688     22058703    *ISRE*          31149                  *PHYHIP*
  cg07776629   chr16        57989122    57989116     57989129    *IRF2*          15898                  *CNGB1*
  cg07776629   chr16        57989122    57989116     57989129    *IRF1*          15898                  *CNGB1*
  cg10692302   chr3         51747227    51747225     51747244    *HNF4*          6147                   *GRM2*
  cg06632557   chr11        61313548    61313495     61313505    *HMX1*          −3678                  *SYT7*
  cg00155846   chr9         138011566   138011506    138011522   *HAND1E47*      14081                  *OLFM1*
  cg11025960   chr3         51749188    51749181     51749190    *GATA3*         8108                   *GRM2*
  cg11025960   chr3         51749188    51749179     51749193    *GATA1*         8108                   *GRM2*
  cg04625615   chr15        41788368    41788310     41788321    *GATA3*         2313                   *ITPKA*
  cg05392169   chr9         138011814   138011802    138011816   *FOXO3*         14329                  *OLFM1*
  cg05289873   chr17        40321636    40321585     40321597    *CREB*          11660                  *KCNH4*
  cg12309456   chr17        74475402    74475346     74475357    *CP2*           2225                   *RHBDF2*
  cg12163800   chr17        74475355    74475346     74475357    *CP2*           2272                   *RHBDF2*
  cg07012189   chr14        93408043    93408038     93408062    *COMP1*         18599                  *CHGA*
  cg04585209   chr11        6292311     6292251      6292269     *CMYB*          306                    *CCKBR*
  cg05392169   chr9         138011814   138011806    138011824   *CMYB*          14329                  *OLFM1*
  cg05934090   chr22        38823188    38823137     38823161    *BRACH*         949                    *KCNJ4*
  cg10368536   chr16        67518179    67518168     67518184    *ARP1*          −463                   *AGRP*
  cg06191091   chr17        30583855    30583847     30583863    *ARNT*          −9339                  *RHBDL3*
  cg03358506   chr8         22058702    22058694     22058703    *AREB6*         31149                  *PHYHIP*

ID, probe number in methylation chip; MAPINFO, methylation position; tfbs_start, the starting point in transcription factor binding sites; tfbs_end, the end point in transcription factor binding sites; TF, transcription factor; Distance_closest_TSS, the nearest transcription start point position; Closest_TSS_gene_name, the nearest gene.

###### 

GO analysis of the differentially expressed genes.

  Category        Term                                                      Count   P-value   FDR
  --------------- --------------------------------------------------------- ------- --------- --------
  GOTERM_BP_FAT   GO:0006813-potassium ion transport                          3     0.013     14.588
  GOTERM_BP_FAT   GO:0007242-intracellular signaling cascade                  5     0.044     41.371
  GOTERM_BP_FAT   GO:0015672-monovalent inorganic cation transport            3     0.047     43.728
  GOTERM_BP_FAT   GO:0006811-ion transport                                    4     0.050     45.428
  GOTERM_CC_FAT   GO:0034703-cation channel complex                           3     0.012     10.880
  GOTERM_CC_FAT   GO:0044459-plasma membrane part                             8     0.012     11.321
  GOTERM_CC_FAT   GO:0005886-plasma membrane                                10      0.023     20.748
  GOTERM_CC_FAT   GO:0034702-ion channel complex                              3     0.026     23.371
  GOTERM_MF_FAT   GO:0005509-calcium ion binding                              7     \<0.001   0.864
  GOTERM_MF_FAT   GO:0005261-cation channel activity                          4     0.005     5.578
  GOTERM_MF_FAT   GO:0022836-gated channel activity                           4     0.007     7.698
  GOTERM_MF_FAT   GO:0046873-metal ion transmembrane transporter activity     4     0.008     8.936
  GOTERM_MF_FAT   GO:0030955-potassium ion binding                            3     0.012     12.513
  GOTERM_MF_FAT   GO:0005267-potassium channel activity                       3     0.013     13.401
  GOTERM_MF_FAT   GO:0005216-ion channel activity                             4     0.013     13.593
  GOTERM_MF_FAT   GO:0022838-substrate specific channel activity              4     0.014     14.678
  GOTERM_MF_FAT   GO:0015267-channel activity                                 4     0.015     15.992
  GOTERM_MF_FAT   GO:0022803-passive transmembrane transporter activity       4     0.016     16.088
  GOTERM_MF_FAT   GO:0046872-metal ion binding                              11      0.020     20.008
  GOTERM_MF_FAT   GO:0043169-cation binding                                 11      0.021     21.264
  GOTERM_MF_FAT   GO:0043167-ion binding                                    11      0.024     23.361
  GOTERM_MF_FAT   GO:0004435-phosphoinositide phospholipase C activity        2     0.032     30.645
  GOTERM_MF_FAT   GO:0031420-alkali metal ion binding                         3     0.035     32.899
  GOTERM_MF_FAT   GO:0004629-phospholipase C activity                         2     0.040     36.483

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; counts, numbers of DEGs; FDR, false discovery rate.
